Agenda March 18, 2027: Main Conference Day Two - PT (Pacific Time, GMT-08:00)
A major opportunity to reduce CLD timelines lies in reducing manual effort and improving screening efficiency. This session will examine high-throughput clone screening, automation, data-rich selection workflows, and the use of smarter decision frameworks to reduce experimental burden. It also creates a natural home for practical digital and AI-enabled CLD workflows.
As portfolios shift toward more complex molecules, companies are rethinking how far CLD standardization can stretch. This panel will explore where platform approaches still create major speed advantages, where they begin to fail, and how teams decide when to customize.
CLD performance increasingly depends on how organizations balance scientific depth, speed, platform leverage, and cross-functional alignment. This session will focus on team design, investment choices, and workflow structures that help CLD organizations accelerate without compromising quality or manufacturability. It is designed to attract directors and heads of development.
As development timelines compress, cell line development teams are being asked to make earlier decisions with greater downstream consequences. This session will focus on clone selection, stability assessment, developability screening, and early product-quality evaluation to reduce risk before molecules move deeper into process development. Talks will show how earlier insight can prevent late-stage rework and manufacturability issues.
As pipelines become more complex, leaders need to determine how CLD organizations should evolve to support speed, manufacturability, and long-term competitiveness. This session will connect molecule trends with organizational and technology investment decisions.